Cargando…

Abnormal Crosstalk between Endothelial Cells and Podocytes Mediates Tyrosine Kinase Inhibitor (TKI)-Induced Nephrotoxicity

Vascular endothelial growth factor A (VEGFA) and its receptor VEGFR2 are the main targets of antiangiogenic therapies, and proteinuria is one of the common adverse events associated with the inhibition of the VEGFA/VEGFR2 pathway. The proteinuric kidney damage induced by VEGFR2 tyrosine kinase inhib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gu, Xiaoying, Zhang, Su, Zhang, Ti
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8070074/ https://www.ncbi.nlm.nih.gov/pubmed/33921219 http://dx.doi.org/10.3390/cells10040869

Ejemplares similares

Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma
por: Lai, Yongchang, et al.
Publicado: (2018)

BECLIN1 Is Essential for Podocyte Secretory Pathways Mediating VEGF Secretion and Podocyte-Endothelial Crosstalk
por: Bork, Tillmann, et al.
Publicado: (2022)

Diabetic Kidney Disease, Endothelial Damage, and Podocyte-Endothelial Crosstalk
por: Gil, Cindy Lora, et al.
Publicado: (2020)

PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PET
por: van Dongen, Guus A. M. S., et al.
Publicado: (2012)

Monitoring the Response to Tyrosine Kinase Inhibitor (TKI) Treatment in Chronic Myeloid Leukemia (CML)
por: Haznedaroglu, Ibrahim C.
Publicado: (2014)

BCR-ABL tyrosine kinase inhibitor (TKI)-induced nephropathy: An under-recognized phenomenon
por: Stanchina, Michele, et al.
Publicado: (2020)

Tyrosine Kinase Signaling in Kidney Glomerular Podocytes
por: Hattori, Seisuke, et al.
Publicado: (2011)

Glomerular Endothelial Cell Crosstalk With Podocytes in Diabetic Kidney Disease
por: Mahtal, Nassim, et al.
Publicado: (2021)

Endothelial-Podocyte Crosstalk: The Missing Link Between Endothelial Dysfunction and Albuminuria in Diabetes
por: Siddiqi, Ferhan S., et al.
Publicado: (2013)

Influence of Tyrosine Kinase Inhibitors on Hypertension and Nephrotoxicity in Metastatic Renal Cell Cancer Patients
por: Semeniuk-Wojtaś, Aleksandra, et al.
Publicado: (2016)

Podocytes Regulate Neutrophil Recruitment by Glomerular Endothelial Cells via IL-6–Mediated Crosstalk
por: Kuravi, Sahithi J., et al.
Publicado: (2014)

Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer
por: Gijtenbeek, Rolof G.P., et al.
Publicado: (2022)

Second-Generation Tyrosine Kinase Inhibitors (Tki) as Salvage Therapy for Resistant or Intolerant Patients to Prior TKIs
por: Breccia, Massimo, et al.
Publicado: (2014)

Clinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials
por: Kim, Sungkyoung, et al.
Publicado: (2014)

Renal tubular Bim mediates the tubule-podocyte crosstalk via NFAT2 to induce podocyte cytoskeletal dysfunction
por: Xu, Chunmei, et al.
Publicado: (2020)

AB011. Thymoma in patient receiving tyrosine kinase inhibitor (TKI) treatment: morphological aspects and surgical approach
por: Cattaneo, Margherita, et al.
Publicado: (2022)

Disruption of podocyte cytoskeletal biomechanics by dasatinib leads to nephrotoxicity
por: Calizo, Rhodora C., et al.
Publicado: (2019)

The effect of mycophenolate mofetil on podocytes in nephrotoxic serum nephritis
por: Hackl, A., et al.
Publicado: (2023)

Role of chemotherapy with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) rechallenge in small cell transformation after EGFR-TKI failure: a case report
por: Lee, Sanghun, et al.
Publicado: (2018)

A Receptor Tyrosine Kinase Inhibitor, Dovitinib (TKI-258), Enhances BMP-2-Induced Osteoblast Differentiation In Vitro
por: Lee, Yura, et al.
Publicado: (2016)

Myocardial Infarction after Long-Term Treatment with a Tyrosine Kinase Inhibitor (TKI) with Anti-VEGF Receptor Activity
por: Paschke, L., et al.
Publicado: (2019)

Reviewing Treatment Options for Advanced Renal Cell Carcinoma: Is There Still a Place for Tyrosine Kinase Inhibitor (TKI) Monotherapy?
por: Fontes-Sousa, Mário, et al.
Publicado: (2022)

Correlation Between Circulating Tumor DNA Levels and Response to Tyrosine Kinase Inhibitors (TKI) Treatment in Non-Small Cell Lung Cancer
por: Wei, Zhangjing, et al.
Publicado: (2017)

Anti-Anaplastic Thyroid Cancer (ATC) Effects and Mechanisms of PLX3397 (Pexidartinib), a Multi-Targeted Tyrosine Kinase Inhibitor (TKI)
por: Luo, Jingtao, et al.
Publicado: (2022)

LDP alleviates TKI-induced proteinuria through reversing the expression of RelA in renal tissues
por: Fu, Zhou, et al.
Publicado: (2023)

The assessment of side effects of tyrosine kinase inhibitors (TKI) applied in patients with advanced thyroid cancer (TC) - one centre experience
por: Krajewska, Jolanta, et al.
Publicado: (2013)

The diabetic microenvironment causes mitochondrial oxidative stress in glomerular endothelial cells and pathological crosstalk with podocytes
por: Casalena, Gabriella A., et al.
Publicado: (2020)

The crosstalk between glomerular endothelial cells and podocytes controls their responses to metabolic stimuli in diabetic nephropathy
por: Albrecht, Michael, et al.
Publicado: (2023)

Psychological Factors Affecting the Willingness to Accept a Possible Tyrosine Kinase Inhibitor (TKI) Discontinuation in Chronic Myeloid Leukaemia (CML) Patients
por: Cutica, Ilaria, et al.
Publicado: (2022)

Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
por: Yao, Yu, et al.
Publicado: (2023)

Survival analysis of patients with advanced non‐small cell lung cancer receiving tyrosine kinase inhibitor (TKI) treatment: A multi‐center retrospective study
por: Shi, Qingming, et al.
Publicado: (2017)

Can EGFR-Tyrosine Kinase Inhibitors (TKI) Alone Without Talc Pleurodesis Prevent Recurrence of Malignant Pleural Effusion (MPE) in Lung Adenocarcinoma
por: Verma, Akash, et al.
Publicado: (2016)

Elevating CDCA3 Levels Enhances Tyrosine Kinase Inhibitor Sensitivity in TKI-Resistant EGFR Mutant Non-Small-Cell Lung Cancer
por: Sahin, Katherine B., et al.
Publicado: (2021)

Prognostic value of skeletal muscle mass during tyrosine kinase inhibitor (TKI) therapy in cancer patients: a systematic review and meta-analysis
por: Rinninella, Emanuele, et al.
Publicado: (2020)

Case report: Long-term voluntary Tyrosine Kinase Inhibitor (TKI) discontinuation in chronic myeloid leukemia (CML): Molecular evidence of an immune surveillance
por: Imeri, Jusuf, et al.
Publicado: (2023)

ARF6 mediates nephrin tyrosine phosphorylation-induced podocyte cellular dynamics
por: Lin, Jamie S., et al.
Publicado: (2017)

1790 Targeting filarial kinases with human homologues: repurposed, orally available, approved tyrosine kinase inhibitors (TKI) act as micro- and macrofilaricidal agents at concentrations easily achievable in vivo
por: O'connell, Elise, et al.
Publicado: (2014)

Quality of life in lung cancer survivors treated with tyrosine-kinase inhibitors (TKI): results from the multi-centre cross-sectional German study LARIS
por: Riccetti, Nicola, et al.
Publicado: (2022)

Podocyte-specific deletion of signal transducer and activator of transcription 3 attenuates nephrotoxic serum-induced glomerulonephritis
por: Dai, Yan, et al.
Publicado: (2013)

Impact of Weight Loss at Presentation on Survival in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI) Sensitive Mutant Advanced Non-small Cell Lung Cancer (NSCLC) Treated with First-line EGFR-TKI
por: Lin, Liping, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_jj8ah296d7dpqah3sncafb0bu0